The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Enrique Gallardo
Honoraria - Advanced Accelerator Applications; AstraZeneca Spain; Bayer; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Ipsen; LEO Pharma; Pfizer; Recordati; Rovi; Sanofi
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol-Myers Squibb; EUSA Pharma; GlaxoSmithKline; Ipsen; MSD Oncology; Pfizer; Recordati
Speakers' Bureau - Advanced Accelerator Applications; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; LEO Pharma; MSD Oncology; Rovi; Sanofi/Aventis
Travel, Accommodations, Expenses - AstraZeneca Spain; Bayer; Ipsen; MSD Oncology; Recordati
 
Bertrand Tombal
Honoraria - AAA/Endocyte/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Ferring; Janssen; MSD Oncology; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer/Astellas; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; Janssen
Research Funding - Ferring (Inst)
Expert Testimony - Steba Biotech
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi
 
Ananya Choudhury
Honoraria - AstraZeneca (Inst); Bayer (Inst); BMJ Oncology (Inst); Merck; MSD (Inst)
Research Funding - Cancer Research UK; Elekta (Inst); National Institute of Health Research (NIHR); Prostate Cancer UK
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Research Funding - Abbvie (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Point Therapeutics (Inst); Sanofi (Inst)
 
Andrey Soares
Honoraria - AstraZeneca; Bayer; Janssen; Merck Serono; MSD; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Bayer; Janssen; MSD; Novartis; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Adium Pharma; Bayer; Ipsen; Janssen; Merck Serono; MSD
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Raymond McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Alejo Rodriguez-Vida
No Relationships to Disclose
 
Pedro Isaacsson Velho
No Relationships to Disclose
 
Felipe Cruz
No Relationships to Disclose
 
Thierry Roumeguere
No Relationships to Disclose
 
Gedske Daugaard
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb/Pfizer; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Bayer; Merck
 
Rosely Yamamura
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS Brazil (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Exelixis (Inst); Gilead Sciences (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Frederic Lecouvet
No Relationships to Disclose
 
Corneel Coens
No Relationships to Disclose
 
Coralie Poncet
No Relationships to Disclose
 
Beatrice Fournier
No Relationships to Disclose
 
Silke Gillessen
Employment - Ente Ospedaliero Cantonale
Honoraria - Avalere Health (Inst); EPG Health (Inst); Medtoday Switzerland (Inst); Orikata (Inst); UroPractica Group in São Paulo (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); EPG Health (Inst); GlaxoSmithKline (Inst); InnoMedica (Inst); Ipsen (Inst); LinkinVax (Inst); Macrogenics (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); PeerVoice (Inst); Pfizer (Inst)
Speakers' Bureau - AdMeTech Foundation (Inst); ASCO GU (Inst); Avalere Health (Inst); EPG Health (Inst); ESMO; ESMO (Inst); Intellisphere (Inst); Medtoday Switzerland (Inst); Meister ConCept GmbH (Inst); Orikata (Inst); Schweizerische Gesellschaft für Medizinische Onkologie; Silvia Grasso Consulting (Inst); Swiss Group for Clinical Cancer Research (SAKK) (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1); WO2009138392
Travel, Accommodations, Expenses - Bayer; Gilead Sciences; Intellisphere; Johnson & Johnson/Janssen
Other Relationship - University of Applied Sciences and Arts of Southern Switzerland (SUPSI)